Aperio Group’s Regenxbio RGNX Stock Holding History

Aperio Group’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$451K	Buy	+9,938	New	+$347K	﹤0.01%	2013
2020 Q1	–	Sell	-6,397	Closed	-$262K	–	2386
2019 Q4	$262K	Buy	+6,397	New	+$253K	﹤0.01%	2108
2019 Q3	–	Sell	-5,204	Closed	-$267K	–	2665
2019 Q2	$267K	Buy	5,204 +486	+10%	+$24.3K	﹤0.01%	2066
2019 Q1	$270K	Buy	+4,718	New	+$234K	﹤0.01%	2052

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Korea Investment Corp Seoul, South Korea $48.3B AUM 31.57% 1-Year Est. Return

Aperio Group's RGNX Position: Q4 2020 in Review

Aperio Group opened a new position in Regenxbio (RGNX) in Q4 2020: 9,938 shares worth $451K. The stake represents ﹤0.01% of the portfolio and ranks #2013 among its holdings. This is a return to the name: Aperio Group previously reported a position in RGNX as recently as Q4 2019.

Aperio Group first reported a position in RGNX in Q1 2019 and has held it in 4 quarters since. 187 funds tracked by Wall St. Rank hold RGNX as of Q4 2020.

Aperio Group held 9,938 shares of Regenxbio worth $451K as of Q4 2020.
Regenxbio was a new Aperio Group position in Q4 2020.
Regenxbio made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2013 holding.
Aperio Group first reported a position in Regenxbio in Q1 2019 and has held it in 4 quarters since.
187 funds tracked by Wall St. Rank held Regenxbio as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.